Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. 1999

S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
Department of Urology, Dokkyo University School of Medicine, Mibu, Tochigi, Japan.

The objective of this study was to elucidate the mechanism underlying the further suppression of serum testosterone (T) by diethylstilbestrol diphosphate (DES-DP) in patients with prostate cancer refractory to hormonal treatment. These patients received an LHRH agonist with or without a non-steroidal androgen-receptor blocker or a gestagen before DES-DP. We measured serum levels of total and free T, dihydrotestosterone (DHT), estradiol (E2), dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), androstenedione, cortisol, aldosterone before and during intravenous administration of high doses of DES-DP (500 or 1000 mg/day). DES-DP administration suppressed the serum levels of FSH (p=0.04) and total T (p=0.02), and eliminated free T (p=0.04) and E2 (p=0.04) from serum, while reducing serum DHEA-S to approximately two-thirds of the pretreatment level (p=0.03). In contrast, serum levels of SHBG (p=0.02) and cortisol (p=0.02) were markedly increased after DES-DP administration. The latter had no significant effect on serum levels of LH, DHT, ACTH, 17alpha-hydroxypregnenolone, 17alpha-hydroxyprogesterone, DHEA, androstenedione, or aldosterone. The results suggest that the potent suppression of circulating total T by DES-DP is caused, in part, by the inhibitory effect of DES-DP on serum DHEA-S level. In most patients, high-dose DES-DP treatment completely suppressed the serum level of free T, while possibly elevating serum SHBG and decreasing serum total T. The mechanisms that maintain the serum level of serum DHT during DES-DP treatment require further elucidation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002715 Chlormadinone Acetate An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL). Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro-,Chlormadinon Acetate,Chlormadinone,Chlormadinone Acetate, (9 beta,10 alpha)-Isomer,Neo-Eunomin,Neo Eunomin,NeoEunomin
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
August 1998, Nihon rinsho. Japanese journal of clinical medicine,
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
December 2002, Nihon rinsho. Japanese journal of clinical medicine,
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
September 2001, Scandinavian journal of urology and nephrology,
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
April 1994, Revue du rhumatisme (Ed. francaise : 1993),
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
August 1985, Cancer,
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
August 1980, The Journal of urology,
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
August 2011, Zhonghua yi xue za zhi,
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
July 1956, Deutsche medizinische Wochenschrift (1946),
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
December 2007, Hinyokika kiyo. Acta urologica Japonica,
S Kitahara, and H Umeda, and M Yano, and F Koga, and S Sumi, and H Moriguchi, and Y Hosoya, and M Honda, and K Yoshida
April 2003, International journal of clinical oncology,
Copied contents to your clipboard!